Description
Composition- Linagliptin 5 mg + Dapagliflozin 10 mg + Metformin 500 mg
Mode of Action- Combines incretin enhancement, renal glucose excretion and insulin sensitization for comprehensive glycemic control across multiple pathways.
USPs- Triple mechanism diabetes control; useful in uncontrolled type 2 diabetes; supports fasting and postprandial glucose management.
Prescribing Specialties- Diabetologist, Internal Medicine
